Influx Healthtech Ltd, a Mumbai-based Contract Development & Manufacturing Organization (CDMO), is launching its IPO on NSE Emerge. The issue comprises a fresh issue and an Offer for Sale (OFS).
- IPO Opening (DRHP filed): 4 Feb 2025
- Listing Platform: NSE Emerge
🏭 Company Overview
Influx Healthtech Ltd, established in 2020 and based in Mumbai, operates as a Contract Development and Manufacturing Organization (CDMO). The company specializes in manufacturing a wide range of products across various categories including:
- Nutraceuticals
- Cosmetics
- Ayurvedic/Herbal Products
- Veterinary Feed Supplements
- Homecare Products
Influx Healthtech provides end-to-end solutions under private labeling and contract manufacturing for domestic and international clients. With three state-of-the-art manufacturing facilities located in Palghar, Maharashtra, the company is well-equipped to meet high-volume demands and adhere to international quality standards.
The facilities are certified with WHO-GMP, ISO 22000:2018, ISO 14001:2015, HACCP, Halal, Kosher, and FDA compliance, enabling the company to cater to regulated markets and build trust across industries.
The company is now expanding into new production lines and capacity through its IPO funding, aiming to strengthen its position in the fast-growing health and wellness manufacturing sector.
Lot Size & Investment Details
| Appy as | Price Band | Lot Size | Share | Appy Upto |
| Retail (Min) | ₹115 – ₹122 | 1 lot | 1,000 shares | ₹1,22,000 |
| Retail (Max) | ₹115 – ₹122 | 1 lot | 1,000 shares | ₹1,22,000 (Retail limit) |
| S-HNI (Min) | ₹115 – ₹122 | 2 lot | 2,000 shares | ₹2,44,000 |
📊 Financial Highlights
| Financial Year | Revenue (₹ Cr) | EBITDA (₹ Cr) | Net Profit (₹ Cr) | Net Worth (₹ Cr) |
|---|
| FY 2021–22 | 45.36 | 6.02 | 4.04 | 15.20 |
| FY 2022–23 | 76.05 | 9.89 | 7.19 | 22.39 |
| FY 2023–24 | 99.96 | 15.38 | 11.22 | 33.61 |
🎯 Objects of the Issue
The net proceeds from the IPO will be utilized for the following purposes:
- Establishment of a New Nutraceutical Manufacturing Facility
- To expand production capacity and cater to growing demand
- Proposed Investment: ₹21.61 crores
- Setting Up a Veterinary Food Manufacturing Unit
- To diversify into the veterinary supplement segment
- Proposed Investment: ₹8.76 crores
- Purchase of Machinery for Homecare and Cosmetics Division
- For improving automation and efficiency in manufacturing
- Proposed Investment: ₹2.66 crores
- General Corporate Purposes
- To support operational and administrative expansion plans
📈 IPO Review & Recommendation
✅ Strengths
- Robust Expansion Plan: Funds are earmarked for new nutraceutical and veterinary manufacturing units, along with machinery for cosmetics and homecare—indicating a well-defined growth strategy.
- Diversified Product Portfolio: Operations span across nutraceuticals, cosmetics, ayurvedic/herbal, veterinary feed, and homecare products, providing stability against sector-specific downturns.
- Strong Financial Momentum: Significant year-over-year growth in revenue and profitability reflects operational efficiency and market demand.
- High-Quality Certifications: Facilities are accredited with WHO-GMP, ISO, HACCP, Halal, Kosher, and FDA approvals, supporting product quality and international market readiness.
⚠️ Risks
- Execution Risk: Timely completion and efficiency of upcoming facilities are critical; any delays may impact financial performance.
- SME Market Volatility: NSE SME listings are known for limited liquidity and potential price fluctuations post-listing.
- Competitive Landscape: Operating in a highly regulated and competitive CDMO space may put pressure on margins and scalability.
📊 Recommendation
The IPO presents a solid opportunity for medium- to long-term investors looking to participate in the growth of the wellness and manufacturing sector. With planned expansion, consistent performance, and regulatory readiness, the offering stands on firm ground. However, investors should remain aware of SME market dynamics and execution-related uncertainties before committing funds.
